Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

• Published in: British journal of cancer Vol. 120; no. 2; pp. 165 - 171
• Main Authors: Mazzaferro, Vincenzo, El-Rayes, Bassel F., Droz dit Busset, Michele, Cotsoglou, Christian, Harris, William P., Damjanov, Nevena, Masi, Gianluca, Rimassa, Lorenza, Personeni, Nicola, Braiteh, Fadi, Zagonel, Vittorina, Papadopoulos, Kyriakos P., Hall, Terence, Wang, Yunxia, Schwartz, Brian, Kazakin, Julia, Bhoori, Sherrie, de Braud, Filippo, Shaib, Walid L.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 22.01.2019; Nature Publishing Group
• Subjects: 631/67/1059/602; 692/4028/67/1504/1329/1326; Adult; Aged; Aged, 80 and over; Alkaloids - administration & dosage; Alkaloids - adverse effects; Asthenia; Biomedical and Life Sciences; Biomedicine; Cancer Research; Chemotherapy; Cholangiocarcinoma; Cholangiocarcinoma - drug therapy; Cholangiocarcinoma - genetics; Cholangiocarcinoma - pathology; Clinical Trials as Topic; Disease control; Drug Resistance; Enzyme inhibitors; Epidemiology; Fatigue; Female; Fibroblast growth factor receptor 2; Fibroblast growth factor receptors; Gene fusion; Humans; Hyperphosphatemia; Kinases; Male; Middle Aged; Molecular Medicine; Mutation; Next-generation sequencing; Oncogene Proteins, Fusion - drug effects; Oncogene Proteins, Fusion - genetics; Oncology; Patients; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Receptor, Fibroblast Growth Factor, Type 2 - genetics; Toxicity; Tumors

Background Next-generation sequencing has identified actionable genetic aberrations in intrahepatic cholangiocarcinomas (iCCA), including the fibroblast growth factor receptor 2 (FGFR2) fusions. Derazantinib (ARQ 087), an orally bioavailable, multi-kinase inhibitor with potent pan-FGFR activity, has...